慢性乙型肝炎的功能性治愈

Functional cure of chronic hepatitis B

由于cccDNA的持续存在,HBV感染难以实现完全治愈。目前抗病毒治疗的理想终点是实现CHB功能性治愈。现有的抗病毒策略包括核苷类似物和聚乙二醇IFN-α在功能性治愈方面的疗效有限。为进一步提高功能性治愈率,靶向HBV生命周期的新型直接作用抗病毒药物和改善宿主免疫应答的免疫调节剂正在开发中。本文总结了CHB现有治疗策略以及直接作用抗病毒药物和免疫调节剂的疗效和安全性。

Due to the persistence of cccDNA,it is difficult to achieve complete or sterilizing cure of HBV infection.The ideal end point of antiviral therapy is to realize the functional cure of chronic hepatitis B(CHB).Current HBV therapeutics including nucleoside analogues and peginterferon-α(Peg-IFN-α)have limited efficacy in functional cure.In order to improve the rate of functional cure,new direct-acting antivirals targeting HBV life cycle and immunomodulators to improve host immune response are being developed.In this article,the existing treatment strategies for CHB,the efficacy and safety of direct-acting antivirals and immunomodulators are summarized.